Daiichi Sankyo Co., Ltd. has entered into an agreement to acquire U3 Pharma AG, a privately held German biotechnology company focusing on antibody research for the treatment of cancer. Daiichi Sankyo will purchase all of the stock and make a one-time payment of $235 million. The transaction is subject to customary closing conditions.     U3 Pharma was founded by Professor Axel Ullrich of the Max Planck Institute of Biochemistry, whose gene technology-based and oncology-focused research led to...